Hepatitis B virus (HBV) can cause severe liver diseases including cirrhosis and hepatocellular carcinoma (HCC). There are approximately 350 million people in the world that are chronically infected by this virus, resulting in 0.5-1 million deaths every year. Most chronic HBV carriers acquired the virus early in life from their infected mothers through vertical transmission. In contrast, patients who acquired HBV from other adults through horizontal transmission will usually develop self-limited acute infection. Why vertical transmission leads to chronic infection whereas horizontal transmission leads to self-limited acute infection is unclear. HBV has a very narrow host range, which has greatly hampered its research. We have recently developed a mouse model to study the maternal effect on HBV persistence in the offspring. By crossing female hemizygous HBV transgenic mice to male nave mice, we obtained non-transgenic mouse pups. When these non-transgenic mouse pups were injected with the HBV genomic DNA by hydrodynamic injection, the HBV replication persisted in the mouse liver for up to seven months. This is in contrast to control mice born to non-transgenic mothers, which cleared HBV after 3-4 weeks of HBV DNA injection. Our further studies indicated that the maternal HBV e antigen (HBeAg) could condition the Kupffer cells of the offspring, which would undergo M2 polarization to support HBV persistence upon re-stimulation by HBeAg. The goal of this application is to continue these previous studies to further investigate how HBeAg interacts with Kupffer cells. Specifically, we will determine how HBeAg stimulates Kupffer cells and to identify the putative HBeAg receptor in these cells. We will also determine whether HBeAg by itself is sufficient to condition Kupffer cells of the offspring to support HBV persistence and whether Kupffer cells by themselves are sufficient to support HBV persistence. We will also test the hypothesis that HBeAg conditions Kupffer cells in utero to suppress the immune response to HBV in the offspring. Finally, we will study the HBV basal core promoter mutant, which has reduced expression of HBeAg and is associated with chronic hepatitis and an increased risk for HCC, to test whether this reduction of HBeAg expression leads to the partial loss of immune tolerance. The proposed studies will provide important information for us to understand the mechanism of HBV persistence after vertical transmission and to improve the treatments for chronic HBV patients.

Public Health Relevance

Hepatitis B virus (HBV) is an important human pathogen. There are approximately 350 million people in the world that are chronically infected by this virus, resulting in 0.5-1 million deaths every year. The goal of our proposed research is to understand how HBV establishes persistent infection. The knowledge gained from our studies will facilitate the development of better treatments for HBV patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI129540-01A1
Application #
9402258
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Koshy, Rajen
Project Start
2017-06-20
Project End
2022-05-31
Budget Start
2017-06-20
Budget End
2018-05-31
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Southern California
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90033
Tian, Yongjun; Ou, Jing-Hsiung James (2018) HBV-specific T cells as a Biomarker for Discontinuation of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Hepatology :
Tsai, Kuen-Nan; Kuo, Cheng-Fu; Ou, Jing-Hsiung James (2018) Mechanisms of Hepatitis B Virus Persistence. Trends Microbiol 26:33-42
Liu, Kai; Lee, Jiyoung; Kim, Ja Yeon et al. (2017) Mitophagy Controls the Activities of Tumor Suppressor p53 to Regulate Hepatic Cancer Stem Cells. Mol Cell 68:281-292.e5